

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by

Cell

184, 2201-2211.e7

DOI: [10.1016/j.cell.2021.02.033](https://doi.org/10.1016/j.cell.2021.02.033)

Citation Report

#	ARTICLE	IF	CITATIONS
1	OUP accepted manuscript. American Journal of Clinical Pathology, 2021, , .	0.4	7
2	Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant. Emerging Microbes and Infections, 2021, 10, 1284-1292.	3.0	25
3	Germline IGHV3-53-encoded RBD-targeting neutralizing antibodies are commonly present in the antibody repertoires of COVID-19 patients. Emerging Microbes and Infections, 2021, 10, 1097-1111.	3.0	25
12	SARS-CoV-2 variants: a new challenge to convalescent serum and mRNA vaccine neutralization efficiency. Signal Transduction and Targeted Therapy, 2021, 6, 151.	7.1	17
14	Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science, 2021, 372, 1418-1423.	6.0	286
15	SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63. Journal of Clinical Investigation, 2021, 131, .	3.9	154
16	Inferring the Association between the Risk of COVID-19 Case Fatality and N501Y Substitution in SARS-CoV-2. Viruses, 2021, 13, 638.	1.5	21
19	Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies. Expert Review of Vaccines, 2021, 20, 365-373.	2.0	139
20	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet, The, 2021, 397, 1351-1362.	6.3	540
22	Intermolecular Interaction Analyses on SARS-CoV-2 Spike Protein Receptor Binding Domain and Human Angiotensin-Converting Enzyme 2 Receptor-Blocking Antibody/Peptide Using Fragment Molecular Orbital Calculation. Journal of Physical Chemistry Letters, 2021, 12, 4059-4066.	2.1	22
26	Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults. JAMA - Journal of the American Medical Association, 2021, 326, 35-45.	3.8	634
27	Antibody evasion by the P.1 strain of SARS-CoV-2. Cell, 2021, 184, 2939-2954.e9.	13.5	519
28	Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet, The, 2021, 397, 2049-2059.	6.3	391
37	Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals. Viruses, 2021, 13, 1135.	1.5	17
38	Use of Lateral Flow Immunoassay to Characterize SARS-CoV-2 RBD-Specific Antibodies and Their Ability to React with the UK, SA and BR P.1 Variant RBDs. Diagnostics, 2021, 11, 1190.	1.3	10
40	Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain. Nature Communications, 2021, 12, 3815.	5.8	44
42	Covid-19 vaccination in patients with multiple myeloma: Focus on immune response. American Journal of Hematology, 2021, 96, 896-900.	2.0	12
44	Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far?. Viruses, 2021, 13, 1192.	1.5	150

#	ARTICLE	IF	CITATIONS
45	Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2. <i>Frontiers in Microbiology</i> , 2021, 12, 676314.	1.5	17
47	Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. <i>Immunity</i> , 2021, 54, 1276-1289.e6.	6.6	112
54	An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. <i>Cell</i> , 2021, 184, 3452-3466.e18.	13.5	205
57	Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7425.	1.8	69
58	Neutralizing Antibody Responses After SARS-CoV-2 Infection in End-Stage Kidney Disease and Protection Against Reinfection. <i>Kidney International Reports</i> , 2021, 6, 1799-1809.	0.4	13
59	Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice. <i>Scientific Reports</i> , 2021, 11, 14917.	1.6	23
60	<scp>COVID</scp>â€19 convalescent plasma cohort study: Evaluation of the association between both donor and recipient neutralizing antibody titers and patient outcomes. <i>Transfusion</i> , 2021, 61, 2295-2306.	0.8	8
61	A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics. <i>Current Medical Science</i> , 2021, 41, 1037-1051.	0.7	136
62	Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC): Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	2.1	94
63	SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. <i>Cell Host and Microbe</i> , 2021, 29, 1124-1136.e11.	5.1	421
65	Potency of BNT162b2 and mRNAâ€1273 vaccineâ€induced neutralizing antibodies against severe acute respiratory syndromeâ€2 variants of concern: A systematic review of in vitro studies. <i>Reviews in Medical Virology</i> , 2022, 32, e2277.	3.9	57
66	Serum Neutralizing Activity against B.1.1.7, B.1.351, and P.1 SARS-CoV-2 Variants of Concern in Hospitalized COVID-19 Patients. <i>Viruses</i> , 2021, 13, 1347.	1.5	12
67	The preparation of N-IgY targeting SARS-CoV-2 and its immunomodulation to IFN-Î³ production in vitro. <i>International Immunopharmacology</i> , 2021, 96, 107797.	1.7	13
68	SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. <i>Cell Reports</i> , 2021, 36, 109415.	2.9	206
70	The SARS-CoV-2 spike L452R-E484Q variant in the Indian B.1.617 strain showed significant reduction in the neutralization activity of immune sera. <i>Precision Clinical Medicine</i> , 2021, 4, 149-154.	1.3	7
71	Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. <i>Nature Medicine</i> , 2021, 27, 1525-1529.	15.2	363
72	Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ Tâ€cell reactivity in infected or vaccinated individuals. <i>Cell Reports Medicine</i> , 2021, 2, 100355.	3.3	490
74	Contemporary narrative review of treatment options for COVID â€19. <i>Respirology</i> , 2021, 26, 745-767.	1.3	12

#	ARTICLE	IF	CITATIONS
75	Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19. <i>Cell Reports</i> , 2021, 36, 109385.	2.9	23
76	Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Induced by Natural Infection or Vaccination: A Systematic Review and Pooled Analysis. <i>Clinical Infectious Diseases</i> , 2022, 74, 734-742.	2.9	88
77	A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations. <i>Cell Reports</i> , 2021, 36, 109433.	2.9	75
79	An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status. <i>Clinical Infectious Diseases</i> , 2022, 74, 1208-1219.	2.9	64
81	SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment. <i>Annual Review of Medicine</i> , 2022, 73, 1-16.	5.0	91
82	SARS-CoV-2 Bearing a Mutation at the S1/S2 Cleavage Site Exhibits Attenuated Virulence and Confers Protective Immunity. <i>MBio</i> , 2021, 12, e0141521.	1.8	33
83	Effect of time and titer in convalescent plasma therapy for COVID-19. <i>IScience</i> , 2021, 24, 102898.	1.9	16
84	Molecular Level Dissection of Critical Spike Mutations in SARS-CoV-2 Variants of Concern (VOCs): A Simplified Review. <i>ChemistrySelect</i> , 2021, 6, 7981-7998.	0.7	18
85	Key Interacting Residues between RBD of SARS-CoV-2 and ACE2 Receptor: Combination of Molecular Dynamics Simulation and Density Functional Calculation. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 4425-4441.	2.5	100
86	Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay. <i>JCI Insight</i> , 2021, 6, .	2.3	33
87	Crucial Mutations of Spike Protein on SARS-CoV-2 Evolved to Variant Strains Escaping Neutralization of Convalescent Plasmas and RBD-Specific Monoclonal Antibodies. <i>Frontiers in Immunology</i> , 2021, 12, 693775.	2.2	38
88	Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 317.	7.1	68
89	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. <i>Lancet HIV</i> , 2021, 8, e474-e485.	2.1	190
90	Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics. <i>ELife</i> , 2021, 10, .	2.8	267
91	Inflammasome activation at the crux of severe COVID-19. <i>Nature Reviews Immunology</i> , 2021, 21, 694-703.	10.6	210
92	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. <i>Cell</i> , 2021, 184, 4220-4236.e13.	13.5	630
93	B cell receptor (BCR) guided mechanotransduction: Critical hypothesis to instruct SARS-CoV-2 specific B cells to trigger proximal signalling and antibody reshaping. <i>Medical Hypotheses</i> , 2021, 153, 110640.	0.8	1
94	An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era. <i>Pathogens</i> , 2021, 10, 1030.	1.2	33

#	ARTICLE	IF	CITATIONS
95	An Analysis Based on Molecular Docking and Molecular Dynamics Simulation Study of Bromelain as Anti-SARS-CoV-2 Variants. <i>Frontiers in Pharmacology</i> , 2021, 12, 717757.	1.6	28
96	N439K Variant in Spike Protein Alter the Infection Efficiency and Antigenicity of SARS-CoV-2 Based on Molecular Dynamics Simulation. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 697035.	1.8	19
97	A Single Amino Acid at Residue 188 of the Hexon Protein Is Responsible for the Pathogenicity of the Emerging Novel Virus Fowl Adenovirus 4. <i>Journal of Virology</i> , 2021, 95, e0060321.	1.5	25
99	B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19. <i>EBioMedicine</i> , 2021, 70, 103539.	2.7	67
100	A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site. <i>Immunity</i> , 2021, 54, 2385-2398.e10.	6.6	46
101	SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants. <i>Viruses</i> , 2021, 13, 1687.	1.5	57
103	The rapid adaptation of SARS-CoV-2â€™rise of the variants: transmission and resistance. <i>Journal of Microbiology</i> , 2021, 59, 807-818.	1.3	18
104	Mutations of SARS-CoV-2 RBD May Alter Its Molecular Structure to Improve Its Infection Efficiency. <i>Biomolecules</i> , 2021, 11, 1273.	1.8	30
106	mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. <i>Nature Immunology</i> , 2021, 22, 1306-1315.	7.0	57
107	Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants. <i>Immunity</i> , 2021, 54, 1841-1852.e4.	6.6	114
110	The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum. <i>EBioMedicine</i> , 2021, 71, 103544.	2.7	38
111	A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine. <i>Frontiers in Immunology</i> , 2021, 12, 729189.	2.2	23
113	The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e627-e637.	2.2	132
114	Revolutionizing polymer-based nanoparticle-linked vaccines for targeting respiratory viruses: A perspective. <i>Life Sciences</i> , 2021, 280, 119744.	2.0	11
115	Evaluation of Cell-Based and Surrogate SARS-CoV-2 Neutralization Assays. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0052721.	1.8	71
116	Zoonotic and anthroozoonotic potential of COVID-19 and its implications for public health. <i>Environmental Science and Pollution Research</i> , 2021, 28, 52599-52609.	2.7	4
117	A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	100
118	An ultrapotent pan-Î²-coronavirus lineage B (Î²-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope. <i>Protein and Cell</i> , 2022, 13, 655-675.	4.8	25

#	ARTICLE	IF	CITATIONS
121	Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination. <i>Science Advances</i> , 2021, 7, eabj5365.	4.7	83
123	Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2021, 12, 752003.	2.2	62
124	Exploring the Interaction between E484K and N501Y Substitutions of SARS-CoV-2 in Shaping the Transmission Advantage of COVID-19 in Brazil: A Modeling Study. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 105, 1247-1254.	0.6	5
125	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T _H 1 response with a diverse TCR repertoire. <i>Science Translational Medicine</i> , 2021, 13, eabj7211.	5.8	80
129	Dynamics of SARS-CoV-2 mutations reveals regional-specificity and similar trends of N501 and high-frequency mutation N501Y in different levels of control measures. <i>Scientific Reports</i> , 2021, 11, 17755.	1.6	19
130	Profiling CD8+ T _H cell epitopes of COVID-19 convalescents reveals reduced cellular immune responses to SARS-CoV-2 variants. <i>Cell Reports</i> , 2021, 36, 109708.	2.9	42
131	The biological and clinical significance of emerging SARS-CoV-2 variants. <i>Nature Reviews Genetics</i> , 2021, 22, 757-773.	7.7	778
132	Chitosan derivatives: A suggestive evaluation for novel inhibitor discovery against wild type and variants of SARS-CoV-2 virus. <i>International Journal of Biological Macromolecules</i> , 2021, 187, 492-512.	3.6	17
134	Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis. <i>Biomedicines</i> , 2021, 9, 1303.	1.4	87
135	The Immune Response to SARS-CoV-2 and Variants of Concern. <i>Viruses</i> , 2021, 13, 1911.	1.5	18
136	Clinical Characterization and Genomic Analysis of Samples from COVID-19 Breakthrough Infections during the Second Wave among the Various States of India. <i>Viruses</i> , 2021, 13, 1782.	1.5	70
137	Recent progress on the mutations of SARS-CoV-2 spike protein and suggestions for prevention and controlling of the pandemic. <i>Infection, Genetics and Evolution</i> , 2021, 93, 104971.	1.0	19
138	Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2. <i>Journal of Clinical Virology</i> , 2021, 142, 104912.	1.6	8
139	Superior cellular and humoral immunity toward SARS-CoV-2 reference and alpha and beta VOC strains in COVID-19 convalescent as compared to the prime boost BNT162b2-vaccinated dialysis patients. <i>Kidney International</i> , 2021, 100, 698-700.	2.6	8
140	Synthesis, Structural Characterizations, and Quantum Chemical Investigations on 1-(3-Methoxy-phenyl)-3-naphthalen-1-yl-propenone. <i>ACS Omega</i> , 2021, 6, 25982-25995.	1.6	16
141	A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19. <i>Nature Communications</i> , 2021, 12, 5469.	5.8	102
142	The real-life impact of vaccination on COVID-19 mortality in Europe and Israel. <i>Public Health</i> , 2021, 198, 230-237.	1.4	70
143	Specific CD8+ TCR Repertoire Recognizing Conserved Antigens of SARS-CoV-2 in Unexposed Population: A Prerequisite for Broad-Spectrum CD8+ T Cell Immunity. <i>Vaccines</i> , 2021, 9, 1093.	2.1	6

#	ARTICLE	IF	CITATIONS
144	mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. <i>Immunity</i> , 2021, 54, 2893-2907.e5.	6.6	107
145	Pseudoephedrine and its derivatives antagonize wild and mutated severe acute respiratory syndrome <sc>â€CoV</sc>â€2 viruses through blocking virus invasion and antiinflammatory effect. <i>Phytotherapy Research</i> , 2021, 35, 5847-5860.	2.8	8
147	The Natural Stilbenoid (â€“) -Hopeaphenol Inhibits Cellular Entry of SARS-CoV-2 USA-WA1/2020, B.1.1.7, and B.1.351 Variants. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0077221.	1.4	26
149	Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected. <i>Journal of Infection</i> , 2021, 83, 467-472.	1.7	28
150	Controversy surrounding the Sputnik V vaccine. <i>Respiratory Medicine</i> , 2021, 187, 106569.	1.3	28
151	Trajectory of Growth of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in Houston, Texas, January through May 2021, Based on 12,476 Genome Sequences. <i>American Journal of Pathology</i> , 2021, 191, 1754-1773.	1.9	26
152	Cellular Immune Responses are Preserved and May Contribute to Chadox1 ChAdOx1 nCoV-19 Vaccine Effectiveness Against Infection Due to SARS-CoV-2 BÂ·1Â·617Â·2 Delta Variant Despite Reduced Virus Neutralisation. <i>SSRN Electronic Journal</i> , 0, , .	0.4	8
153	VarEPS: an evaluation and prewarning system of known and virtual variations of SARS-CoV-2 genomes. <i>Nucleic Acids Research</i> , 2022, 50, D888-D897.	6.5	18
154	Impact of second wave of COVID-19 on health care workers in India. <i>Apollo Medicine</i> , 2021, .	0.0	0
156	N-terminal domain mutations of the spike protein are structurally implicated in epitope recognition in emerging SARS-CoV-2 strains. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 5556-5567.	1.9	39
157	Divergence of Delta and Beta Variants and SARS-CoV-2 Evolved in Advanced HIV Disease into Two Serological Phenotypes. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
158	Global Prevalence of Adaptive and Prolonged Infectionsâ€™ Mutations in the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein. <i>Viruses</i> , 2021, 13, 1974.	1.5	9
159	Functional Effects of Receptor-Binding Domain Mutations of SARS-CoV-2 B.1.351 and P.1 Variants. <i>Frontiers in Immunology</i> , 2021, 12, 757197.	2.2	20
160	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. <i>Cell</i> , 2021, 184, 5699-5714.e11.	13.5	262
161	Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 202-221.	2.8	569
162	Imidazoles and benzimidazoles as putative inhibitors of SARS-CoV-2 B.1.1.7 (Alpha) and P.1 (Gamma) variant spike glycoproteins: A computational approach. <i>Chemical Papers</i> , 2021, , 1-11.	1.0	4
163	COVID-19 Risk Assessment for the Tokyo Olympic Games. <i>Frontiers in Public Health</i> , 2021, 9, 730611.	1.3	9
164	Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. <i>Nature Microbiology</i> , 2021, 6, 1433-1442.	5.9	94

#	ARTICLE	IF	CITATIONS
165	Real-time quantification of the transmission advantage associated with a single mutation in pathogen genomes: a case study on the D614G substitution of SARS-CoV-2. <i>BMC Infectious Diseases</i> , 2021, 21, 1039.	1.3	2
166	Vaccinated Patients Admitted in ICU with Severe Pneumonia Due to SARS-CoV-2: A Multicenter Pilot Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 1086.	1.1	9
167	Biological Significance of the Genomic Variation and Structural Dynamics of SARS-CoV-2 B.1.617. <i>Frontiers in Microbiology</i> , 2021, 12, 750725.	1.5	11
168	Effect of Prophylactic Use of Intranasal Oil Formulations in the Hamster Model of COVID-19. <i>Frontiers in Pharmacology</i> , 2021, 12, 746729.	1.6	19
169	Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines. <i>Viruses</i> , 2021, 13, 2127.	1.5	6
170	Mechanism of a COVID-19 nanoparticle vaccine candidate that elicits a broadly neutralizing antibody response to SARS-CoV-2 variants. <i>Science Advances</i> , 2021, 7, eabj3107.	4.7	23
171	A practical approach to SARS-CoV-2 testing in a pre and post-vaccination era. <i>Journal of Clinical Virology Plus</i> , 2021, 1, 100044.	0.4	2
172	Anti-spike antibody response to natural SARS-CoV-2 infection in the general population. <i>Nature Communications</i> , 2021, 12, 6250.	5.8	88
174	Survey of SARS-CoV-2 genetic diversity in two major Brazilian cities using a fast and affordable Sanger sequencing strategy. <i>Genomics</i> , 2021, 113, 4109-4115.	1.3	9
176	A review of epidemiology, clinical features and disease course, transmission dynamics, and neutralization efficacy of SARS-CoV-2 variants. <i>Egyptian Journal of Bronchology</i> , 2021, 15, .	0.3	4
177	Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape. <i>Frontiers in Immunology</i> , 2021, 12, 744242.	2.2	44
178	Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2. <i>Theranostics</i> , 2022, 12, 1-17.	4.6	6
179	Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 473-482.	4.6	76
180	Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal antibodies and neutralizing antibodies induced by infection and vaccination. <i>Emerging Microbes and Infections</i> , 2022, 11, 18-29.	3.0	25
181	The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice. <i>ELife</i> , 2021, 10, .	2.8	24
182	The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview. <i>Vaccines</i> , 2021, 9, 1345.	2.1	22
183	Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. <i>Lancet Microbe</i> , The, 2022, 3, e52-e61.	3.4	436
184	Direct comparison of antibody responses to four SARS-CoV-2 vaccines in Mongolia. <i>Cell Host and Microbe</i> , 2021, 29, 1738-1743.e4.	5.1	61

#	ARTICLE	IF	CITATIONS
185	Immune response against SARS-CoV-2 variants: the role of neutralization assays. <i>Npj Vaccines</i> , 2021, 6, 142.	2.9	26
186	Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges. <i>Biomedicines</i> , 2021, 9, 1740.	1.4	16
187	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. <i>Seminars in Immunology</i> , 2021, 55, 101533.	2.7	72
188	Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 771242.	2.2	15
189	SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021. <i>Microbiology Spectrum</i> , 2021, 9, e0109621.	1.2	39
190	MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2021, 12, 778829.	2.2	2
192	A Strategy to Detect Emerging Non-Delta SARS-CoV-2 Variants with a Monoclonal Antibody Specific for the N501 Spike Residue. <i>Diagnostics</i> , 2021, 11, 2092.	1.3	6
193	Advances in mRNA and other vaccines against MERS-CoV. <i>Translational Research</i> , 2022, 242, 20-37.	2.2	11
194	The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants. <i>Cell Host and Microbe</i> , 2022, 30, 53-68.e12.	5.1	52
195	SARS-CoV-2 exposure in Malawian blood donors: an analysis of seroprevalence and variant dynamics between January 2020 and July 2021. <i>BMC Medicine</i> , 2021, 19, 303.	2.3	45
196	Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape. <i>Cell</i> , 2021, 184, 6229-6242.e18.	13.5	72
197	SARS-CoV-2 spike evolutionary behaviors; simulation of N501Y mutation outcomes in terms of immunogenicity and structural characteristic. <i>Journal of Cellular Biochemistry</i> , 2022, 123, 417-430.	1.2	9
198	SNP and Phylogenetic Characterization of Low Viral Load SARS-CoV-2 Specimens by Target Enrichment. <i>Frontiers in Virology</i> , 2021, 1, .	0.7	6
199	Correlation of the Commercial Anti-SARS-CoV-2 Receptor Binding Domain Antibody Test with the Chemiluminescent Reduction Neutralizing Test and Possible Detection of Antibodies to Emerging Variants. <i>Microbiology Spectrum</i> , 2021, 9, e0056021.	1.2	20
200	Structure and Mutations of SARS-CoV-2 Spike Protein: A Focused Overview. <i>ACS Infectious Diseases</i> , 2022, 8, 29-58.	1.8	32
201	Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity. <i>Microbiology Spectrum</i> , 2021, 9, e0056121.	1.2	15
202	SIRVVD model-based verification of the effect of first and second doses of COVID-19/SARS-CoV-2 vaccination in Japan. <i>Mathematical Biosciences and Engineering</i> , 2021, 19, 1026-1040.	1.0	8
203	OUP accepted manuscript. <i>Briefings in Bioinformatics</i> , 2022, , .	3.2	2

#	ARTICLE	IF	CITATIONS
204	Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants. <i>Microbiology Spectrum</i> , 2022, 10, e0150421.	1.2	17
205	Isolation and characterization of SARS-CoV-2 Beta variant from UAE travelers. <i>Journal of Infection and Public Health</i> , 2022, 15, 182-186.	1.9	22
206	From delta to Omicron: S1-RBD/S2 mutation/deletion equilibrium in SARS-CoV-2 defined variants. <i>Gene</i> , 2022, 814, 146134.	1.0	97
207	Predictive Profiling of SARS-CoV-2 Variants by Deep Mutational Learning. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
208	On the association between SARS-COV-2 variants and COVID-19 mortality during the second wave of the pandemic in Europe. <i>Journal of Market Access & Health Policy</i> , 2021, 9, 2002008.	0.8	9
210	Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein. <i>Emerging Microbes and Infections</i> , 2022, 11, 351-367.	3.0	19
211	An insight into SARS-CoV-2 structure, pathogenesis, target hunting for drug development and vaccine initiatives. <i>RSC Medicinal Chemistry</i> , 2022, 13, 647-675.	1.7	3
212	High-titer neutralization of Mu and C.1.2 SARS-CoV-2 variants by vaccine-elicited antibodies of previously infected individuals. <i>Cell Reports</i> , 2022, 38, 110237.	2.9	21
213	SARS-CoV-2 omicron variant: Could it be another threat?. <i>Journal of Medical Virology</i> , 2022, 94, 1284-1288.	2.5	24
214	Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1242-1252.e12.	1.5	23
216	mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern. <i>Immunity</i> , 2022, 55, 355-365.e4.	6.6	76
217	Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy. <i>International Journal of Biological Sciences</i> , 2022, 18, 459-472.	2.6	65
218	Immunization with synthetic SARS-CoV-2 S glycoprotein virus-like particles protects macaques from infection. <i>Cell Reports Medicine</i> , 2022, 3, 100528.	3.3	6
219	Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain. <i>Science</i> , 2022, 375, .	6.0	68
220	Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants. <i>Frontiers in Medicine</i> , 2021, 8, 836826.	1.2	15
221	The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines. <i>Frontiers in Medicine</i> , 2021, 8, 806641.	1.2	22
222	SARS-COV-2 Variants: Differences and Potential of Immune Evasion. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 781429.	1.8	154
224	Eight Good Reasons for Careful Monitoring and Evaluation of the Vaccine Campaign against COVID-19: Lessons Learned through the Lombardy Experience for Dealing with Next Challenges. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1073.	1.2	4

#	ARTICLE	IF	CITATIONS
226	SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. <i>Cell</i> , 2022, 185, 467-484.e15.	13.5	788
227	SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. <i>Cell Host and Microbe</i> , 2022, 30, 154-162.e5.	5.1	153
229	CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity. <i>Cell Discovery</i> , 2022, 8, 9.	3.1	12
230	Dynamics of SARS-CoV-2 Alpha (B.1.1.7) variant spread: The wastewater surveillance approach. <i>Environmental Research</i> , 2022, 208, 112720.	3.7	16
232	Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection. <i>Nature Microbiology</i> , 2022, 7, 423-433.	5.9	78
233	Protective action of natural and induced immunization against the occurrence of delta or alpha variants of SARS-CoV-2 infection: a test-negative case-control study. <i>BMC Medicine</i> , 2022, 20, 52.	2.3	7
234	Co-circulation of SARS-CoV-2 Alpha and Gamma variants in Italy, February and March 2021. <i>Eurosurveillance</i> , 2022, 27, .	3.9	20
235	A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations. <i>Frontiers in Immunology</i> , 2022, 13, 801522.	2.2	73
236	Structural and biochemical rationale for enhanced spike protein fitness in delta and kappa SARS-CoV-2 variants. <i>Nature Communications</i> , 2022, 13, 742.	5.8	71
237	Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 42.	7.1	25
238	Emerging SARS-CoV-2 Variants: Genetic Variability and Clinical Implications. <i>Current Microbiology</i> , 2022, 79, 20.	1.0	48
241	Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain. <i>Science</i> , 2021, , eabl6251.	6.0	12
243	COVID-19 Vaccine: Between Myth and Truth. <i>Vaccines</i> , 2022, 10, 349.	2.1	12
244	Population Genomics Approaches for Genetic Characterization of SARS-CoV-2 Lineages. <i>Frontiers in Medicine</i> , 2022, 9, 826746.	1.2	7
245	Cooperative multivalent receptor binding promotes exposure of the SARS-CoV-2 fusion machinery core. <i>Nature Communications</i> , 2022, 13, 1002.	5.8	30
246	Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies. <i>Nature Communications</i> , 2022, 13, 871.	5.8	107
248	Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines. <i>Nature Medicine</i> , 2022, 28, 1072-1082.	15.2	147
249	Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting. <i>Cell Reports</i> , 2022, 38, 110561.	2.9	16

#	ARTICLE	IF	CITATIONS
251	Computation of Antigenicity Predicts SARS-CoV-2 Vaccine Breakthrough Variants. <i>Frontiers in Immunology</i> , 2022, 13, 861050.	2.2	8
252	In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate. <i>Scientific Reports</i> , 2022, 12, 4683.	1.6	33
253	A Recombinant Subunit Vaccine Induces a Potent, Broadly Neutralizing, and Durable Antibody Response in Macaques against the SARS-CoV-2 P.1 (Gamma) Variant. <i>ACS Infectious Diseases</i> , 2022, 8, 825-840.	1.8	3
254	The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines. <i>MBio</i> , 2022, 13, e0297921.	1.8	117
255	Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2. <i>PeerJ</i> , 2022, 10, e13083.	0.9	14
256	Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617. <i>Nature Communications</i> , 2022, 13, 1638.	5.8	11
257	Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination. <i>Journal of Infectious Diseases</i> , 2022, 226, 1372-1381.	1.9	41
258	Impact of new variants on SARS-CoV-2 infectivity and neutralization: A molecular assessment of the alterations in the spike-host protein interactions. <i>IScience</i> , 2022, 25, 103939.	1.9	32
259	SARS-CoV-2 variants, immune escape, and countermeasures. <i>Frontiers of Medicine</i> , 2022, 16, 196-207.	1.5	39
261	Divergent trajectories of antiviral memory after SARS-CoV-2 infection. <i>Nature Communications</i> , 2022, 13, 1251.	5.8	20
262	A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of Concern. <i>Viruses</i> , 2022, 14, 597.	1.5	22
263	Functional analysis of polymorphisms at the S1/S2 site of SARS-CoV-2 spike protein. <i>PLoS ONE</i> , 2022, 17, e0265453.	1.1	8
264	Recent highlights on Omicron as a new SARS-COVID-19 variant: evolution, genetic mutation, and future perspectives. <i>Journal of Drug Targeting</i> , 2022, , 1-11.	2.1	5
265	Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds. <i>Frontiers in Immunology</i> , 2022, 13, 773982.	2.2	10
266	COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron. <i>Vaccines</i> , 2022, 10, 391.	2.1	15
268	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. <i>JCI Insight</i> , 2022, 7, .	2.3	26
269	Evaluating the in vitro efficacy of bovine lactoferrin products against SARS-CoV-2 variants of concern. <i>Journal of Dairy Science</i> , 2022, 105, 2791-2802.	1.4	34
270	Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage. <i>Nature Communications</i> , 2022, 13, 1976.	5.8	27

#	ARTICLE	IF	CITATIONS
271	Molecular Dynamics and MM-PBSA Analysis of the SARS-CoV-2 Gamma Variant in Complex with the hACE-2 Receptor. <i>Molecules</i> , 2022, 27, 2370.	1.7	10
272	Kappa-RBD produced by glycoengineered <i>Pichia pastoris</i> elicited high neutralizing antibody titers against pseudoviruses of SARS-CoV-2 variants. <i>Virology</i> , 2022, 569, 56-63.	1.1	6
273	Systematic profiling of antigen bias in humoral response against SARS-CoV-2. <i>Virus Research</i> , 2022, 312, 198711.	1.1	0
274	The non-pharmaceutical interventions may affect the advantage in transmission of mutated variants during epidemics: A conceptual model for COVID-19. <i>Journal of Theoretical Biology</i> , 2022, 542, 111105.	0.8	5
277	Molecular Evolution of Severe Acute Respiratory Syndrome Coronavirus 2: Hazardous and More Hazardous Strains Behind the Coronavirus Disease 2019 Pandemic and Their Targeting by Drugs and Vaccines. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 763687.	1.8	3
280	SARS-CoV-2 Variants: Mutations and Effective Changes. <i>Biotechnology and Bioprocess Engineering</i> , 2021, 26, 859-870.	1.4	12
281	Tracking SARS-CoV-2 Spike Protein Mutations in the United States (January 2020–March 2021) Using a Statistical Learning Strategy. <i>Viruses</i> , 2022, 14, 9.	1.5	10
282	Chimeric crRNA improves CRISPR–Cas12a specificity in the N501Y mutation detection of Alpha, Beta, Gamma, and Mu variants of SARS-CoV-2. <i>PLoS ONE</i> , 2021, 16, e0261778.	1.1	6
283	A Promising Vaccination Strategy against COVID-19 on the Horizon: Heterologous Immunization. <i>Journal of Microbiology and Biotechnology</i> , 2021, 31, 1601-1614.	0.9	8
284	Targeting conserved N-glycosylation blocks SARS-CoV-2 variant infection in vitro. <i>EBioMedicine</i> , 2021, 74, 103712.	2.7	37
285	In silico Identification of a Viral Surface Glycoprotein Site Suitable for the Development of Low Molecular Weight Inhibitors for Various Variants of the SARS-CoV-2. <i>Mikrobiologichnyĭ Zhurnal</i> , 2021, 84, 34-43.	0.2	1
286	Persistent Maintenance of Atypical Memory B Cells Following SARS-CoV-2 Infection and Vaccination Recall Response. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
287	ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants. <i>Cell Reports</i> , 2022, 39, 110757.	2.9	10
288	Computational prediction of the molecular mechanism of statin group of drugs against SARS-CoV-2 pathogenesis. <i>Scientific Reports</i> , 2022, 12, 6241.	1.6	12
289	Research progress on vaccine efficacy against SARS-CoV-2 variants of concern. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12.	1.4	10
290	Impact of SARS-CoV-2 Gamma lineage introduction and COVID-19 vaccination on the epidemiological landscape of a Brazilian city. <i>Communications Medicine</i> , 2022, 2, .	1.9	32
291	Long-Term, CD4+ Memory T Cell Response to SARS-CoV-2. <i>Frontiers in Immunology</i> , 2022, 13, 800070.	2.2	12
292	Combination Therapy of Ledipasvir and Itraconazole in the Treatment of COVID-19 Patients Coinfected with Black Fungus: An In Silico Statement. <i>BioMed Research International</i> , 2022, 2022, 1-10.	0.9	2

#	ARTICLE	IF	CITATIONS
293	Susceptibility to SARS-CoV-2 Virus Variants of Concern in Mouse Models. Problemy Osobo Opasnykh Infektsii, 2022, , 148-155.	0.2	4
294	Functional Analysis of Spike from SARS-CoV-2 Variants Reveals the Role of Distinct Mutations in Neutralization Potential and Viral Infectivity. Viruses, 2022, 14, 803.	1.5	10
295	Comparison of UK paediatric SARS-CoV-2 admissions across the first and second pandemic waves. Pediatric Research, 2023, 93, 207-216.	1.1	10
296	Evaluation of phytoconstituents of <i>Tinospora cordifolia</i> against K417N and N501Y mutant spike glycoprotein and main protease of SARS-CoV-2- an in silico study. Journal of Biomolecular Structure and Dynamics, 2023, 41, 4106-4123.	2.0	1
297	Evaluation of a Rapid and Accessible Reverse Transcription-Quantitative PCR Approach for SARS-CoV-2 Variant of Concern Identification. Journal of Clinical Microbiology, 2022, 60, e0017822.	1.8	15
298	Infectivity-enhancing antibodies against SARS-CoV-2. Translational and Regulatory Sciences, 2022, 4, 1-4.	0.2	2
300	A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants. Vaccines, 2022, 10, 702.	2.1	18
301	RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge. Translational Research, 2022, 248, 11-21.	2.2	13
302	Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2118312119.	3.3	86
303	COVID-19 vaccine development: milestones, lessons and prospects. Signal Transduction and Targeted Therapy, 2022, 7, 146.	7.1	153
304	An Electrostatically-steered Conformational Selection Mechanism Promotes SARS-CoV-2 Spike Protein Variation. Journal of Molecular Biology, 2022, 434, 167637.	2.0	1
305	Neutralization assays for SARS-CoV-2: Implications for assessment of protective efficacy of COVID-19 vaccines. Indian Journal of Medical Research, 2022, 155, 105.	0.4	2
307	A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. Science Bulletin, 2022, 67, 1372-1387.	4.3	54
308	Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. Cell, 2022, 185, 2116-2131.e18.	13.5	105
311	Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease. Journal of Medicinal Chemistry, 2022, 65, 7561-7580.	2.9	65
312	Real-Word Effectiveness of Global COVID-19 Vaccines Against SARS-CoV-2 Variants: A Systematic Review and Meta-Analysis. Frontiers in Medicine, 0, 9, .	1.2	25
313	Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. BMC Medicine, 2022, 20, .	2.3	149
314	Chimeric Antigen by the Fusion of SARS-CoV-2 Receptor Binding Domain with the Extracellular Domain of Human CD154: A Promising Improved Vaccine Candidate. Vaccines, 2022, 10, 897.	2.1	5

#	ARTICLE	IF	CITATIONS
315	SARS-CoV-2 vaccine challenge based on spike glycoprotein against several new variants. <i>Clinical and Experimental Vaccine Research</i> , 2022, 11, 173.	1.1	0
316	COVID-19 Vaccine Booster Significantly Decreases the Risk of Intensive Care Unit Hospitalization in Heart Failure Patients During the Omicron Variant Wave: A Population-Based Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
317	Neutralizing Antibodies Response against SARS-CoV-2 Variants of Concern Elicited by Prior Infection or mRNA BNT162b2 Vaccination. <i>Vaccines</i> , 2022, 10, 874.	2.1	5
318	Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm's COVID-19 Vaccines. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	33
319	Preclinical evaluation of a plant-derived SARS-CoV-2 subunit vaccine: Protective efficacy, immunogenicity, safety, and toxicity. <i>Vaccine</i> , 2022, 40, 4440-4452.	1.7	17
320	Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. <i>Cell</i> , 2022, 185, 2422-2433.e13.	13.5	532
321	The Cross-Protective Immunity Landscape Among Different SARS-CoV-2 Variant RBDs. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
322	Coronavirus Disease 2019 Vaccinations in Patients With Chronic Liver Disease and Liver Transplant Recipients: An Update. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	8
323	An updated review of SARS-CoV-2 detection methods in the context of a novel coronavirus pandemic. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	19
324	Natural selection plays a significant role in governing the codon usage bias in the novel SARS-CoV-2 variants of concern (VOC). <i>PeerJ</i> , 0, 10, e13562.	0.9	4
325	Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants. <i>Viruses</i> , 2022, 14, 1255.	1.5	30
326	Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment. <i>Vaccine</i> , 2022, 40, 5248-5262.	1.7	9
327	Immunogenicity and Reactogenicity of Ad26.COVS.2 in Korean Adults: A Prospective Cohort Study. <i>Journal of Korean Medical Science</i> , 2022, 37, .	1.1	1
328	The spike glycoprotein of highly pathogenic human coronaviruses: structural insights for understanding infection, evolution and inhibition. <i>FEBS Open Bio</i> , 2022, 12, 1602-1622.	1.0	6
329	Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	59
330	Mapping Genetic Events of SARS-CoV-2 Variants. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	4
331	Impact of the temperature on the interactions between common variants of the SARS-CoV-2 receptor binding domain and the human ACE2. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
332	Persistent Maintenance of Intermediate Memory B Cells Following SARS-CoV-2 Infection and Vaccination Recall Response. <i>Journal of Virology</i> , 2022, 96, .	1.5	11

#	ARTICLE	IF	CITATIONS
334	Declining neutralizing antibody levels after SARS-CoV-2 mRNA vaccination: observational data from community point-of-care testing service in Brno, Czechia. <i>Central European Journal of Public Health</i> , 2022, 30, 111-118.	0.4	0
335	SARS-CoV-2's Variants of Concern: A Brief Characterization. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	31
336	Comparative characterization of antibody responses induced by Ad5-vectored spike proteins of emerging SARS-CoV-2 VOCs. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	5
337	A bibliometric analysis of the 100 most cited articles describing SARS-CoV-2 variants. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	0
340	How concerning is a SARS-CoV-2 variant of concern? Computational predictions and the variants labeling system. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	2
341	Effects of boosted mRNA and adenoviralâ€¢vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination. <i>Journal of Medical Virology</i> , 2022, 94, 5713-5722.	2.5	23
342	Humoral responses to the SARS-CoV-2 spike and receptor binding domain in context of pre-existing immunity confer broad sarbecovirus neutralization. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
343	Latest in COVID-19 Vaccine 'Candidates' Race. <i>Infectious Disorders - Drug Targets</i> , 2022, 22, .	0.4	0
344	Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	2
345	SARS-CoV-2 spike N-terminal domain modulates TMPRSS2-dependent viral entry and fusogenicity. <i>Cell Reports</i> , 2022, 40, 111220.	2.9	24
346	Structural insights into the binding of SARS-CoV-2, SARS-CoV, and hCoV-NL63 spike receptor-binding domain to horse ACE2. <i>Structure</i> , 2022, 30, 1432-1442.e4.	1.6	18
347	Accuracy of Allplex SARS-CoV-2 assay amplification curve analysis for the detection of SARS-CoV-2 variant Alpha. <i>Future Microbiology</i> , 2022, 17, 1125-1131.	1.0	3
348	Structural aspects of SARS-CoV-2 mutations: Implications to plausible infectivity with ACE-2 using computational modeling approach. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 6518-6533.	2.0	9
349	Factors influencing neutralizing antibody titers elicited by coronavirus disease 2019 vaccines. <i>Microbes and Infection</i> , 2023, 25, 105044.	1.0	7
350	The mechanisms of immune response and evasion by the main SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 105044.	1.9	8
351	Antibody-mediated immunity to SARS-CoV-2 spike. <i>Advances in Immunology</i> , 2022, , 1-69.	1.1	12
352	Deep mutational learning predicts ACE2 binding and antibody escape to combinatorial mutations in the SARS-CoV-2 receptor-binding domain. <i>Cell</i> , 2022, 185, 4008-4022.e14.	13.5	55
353	The impact of CoronaVac on the neutralization breadth and magnitude of the antibody response to SARS-CoV-2 viruses. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1

#	ARTICLE	IF	CITATIONS
354	Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humans. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	37
355	Human ACE2 Peptide-Attached Plasmonic-Magnetic Heterostructure for Magnetic Separation, Surface Enhanced Raman Spectroscopy Identification, and Inhibition of Different Variants of SARS-CoV-2 Infections. <i>ACS Applied Bio Materials</i> , 2022, 5, 4454-4464.	2.3	4
356	SARS-CoV-2 variants from COVID-19 positive cases in the Free State province, South Africa from July 2020 to December 2021. <i>Frontiers in Virology</i> , 0, 2, .	0.7	2
359	SARS-CoV-2 variants impact RBD conformational dynamics and ACE2 accessibility. <i>Frontiers in Medical Technology</i> , 0, 4, .	1.3	6
360	Importancia de la vigilancia genómica de SARS-CoV-2 en los tiempos de las vacunas contra la COVID-19. <i>Revista De La Universidad Industrial De Santander Salud</i> , 2022, 54, .	0.0	0
361	COVID-19 vaccine booster significantly decreases the risk of intensive care unit hospitalization in heart failure patients during the Omicron variant wave: A population-based study. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	3
362	Effect on the conformations of the spike protein of SARS-CoV-2 due to mutation. <i>Biotechnology and Applied Biochemistry</i> , 2023, 70, 979-991.	1.4	2
363	Molecular epidemiology of SARS-CoV-2 in healthcare workers and identification of viral genomic correlates of transmissibility and vaccine break through infection: A retrospective observational study from a cancer hospital in eastern India. <i>Indian Journal of Medical Microbiology</i> , 2022, , .	0.3	0
364	Prerequisite for COVID-19 Prediction: A Review on Factors Affecting the Infection Rate. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 12997.	1.2	3
365	Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation. <i>Chemico-Biological Interactions</i> , 2022, 368, 110244.	1.7	4
366	High-Throughput Molecular Dynamics-Based Alchemical Free Energy Calculations for Predicting the Binding Free Energy Change Associated with the Selected Omicron Mutations in the Spike Receptor-Binding Domain of SARS-CoV-2. <i>Biomedicines</i> , 2022, 10, 2779.	1.4	2
367	Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions. <i>Biomedicine and Pharmacotherapy</i> , 2023, 157, 113977.	2.5	66
369	In Silico Approach for the Evaluation of the Potential Antiviral Activity of Extra Virgin Olive Oil (EVOO) Bioactive Constituents Oleuropein and Oleocanthal on Spike Therapeutic Drug Target of SARS-CoV-2. <i>Molecules</i> , 2022, 27, 7572.	1.7	3
370	SARS-CoV-2 variant Alpha has a spike-dependent replication advantage over the ancestral B.1 strain in human cells with low ACE2 expression. <i>PLoS Biology</i> , 2022, 20, e3001871.	2.6	11
371	Binding of human ACE2 and RBD of Omicron enhanced by unique interaction patterns among SARS-CoV-2 variants of concern. <i>Journal of Computational Chemistry</i> , 2023, 44, 594-601.	1.5	28
372	Molecular dynamics study on the strengthening behavior of Delta and Omicron SARS-CoV-2 spike RBD improved receptor-binding affinity. <i>PLoS ONE</i> , 2022, 17, e0277745.	1.1	4
373	Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape. <i>IScience</i> , 2023, 26, 105726.	1.9	9
374	SARS-CoV-2 intra-host single-nucleotide variants associated with disease severity. <i>Virus Evolution</i> , 2022, 8, .	2.2	4

#	ARTICLE	IF	CITATIONS
375	Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination. <i>Biochemical Society Transactions</i> , 2022, 50, 1643-1658.	1.6	6
376	Advanced Plasmonic Nanoparticle-Based Techniques for the Prevention, Detection, and Treatment of Current COVID-19. <i>Plasmonics</i> , 2023, 18, 311-347.	1.8	4
377	Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo. <i>Science Advances</i> , 2022, 8, .	4.7	9
378	Neutralizing and enhancing antibodies against SARS-CoV-2. <i>Inflammation and Regeneration</i> , 2022, 42, .	1.5	6
380	A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75. <i>Cell Reports</i> , 2023, 42, 111903.	2.9	34
381	Thermodynamic analysis of the interactions between human ACE2 and spike RBD of Betacoronaviruses (SARS-CoV-1 and SARS-CoV-2). <i>FEBS Open Bio</i> , 0, , .		2
382	Upregulation of PD-L1 by SARS-CoV-2 promotes immune evasion. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	3
383	New nickel(II) Schiff base complexes as potential tools against SARS-CoV-2 Omicron target proteins: an in silico approach. <i>New Journal of Chemistry</i> , 2023, 47, 2350-2371.	1.4	4
384	Expanding repertoire of SARS-CoV-2 deletion mutations contributes to evolution of highly transmissible variants. <i>Scientific Reports</i> , 2023, 13, .	1.6	3
385	Universal access to vaccines in post-COVID bioeconomy: Redesign for variants of concern and patent protection. , 2023, , 37-76.		0
386	Efficacy and Safety of a Booster Vaccination with Two Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: Results of a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial in Abu Dhabi. <i>Vaccines</i> , 2023, 11, 299.	2.1	5
387	Omics approaches in COVID-19: An overview. , 2023, , 3-21.		0
388	A case of reinfection with a different variant of SARS-CoV-2: case report. <i>The Egyptian Journal of Internal Medicine</i> , 2023, 35, .	0.3	1
389	Robust induction of functional humoral response by a plant-derived Coronavirus-like particle vaccine candidate for COVID-19. <i>Npj Vaccines</i> , 2023, 8, .	2.9	2
390	Biomimetic Nanotechnology for SARS-CoV-2 Treatment. <i>Viruses</i> , 2023, 15, 596.	1.5	1
391	BA.1, BA.2 and BA.2.75 variants show comparable replication kinetics, reduced impact on epithelial barrier and elicit cross-neutralizing antibodies. <i>PLoS Pathogens</i> , 2023, 19, e1011196.	2.1	6
392	Assessment of the Biological Impact of SARS-CoV-2 Genetic Variation Using an Authentic Virus Neutralisation Assay with Convalescent Plasma, Vaccinee Sera, and Standard Reagents. <i>Viruses</i> , 2023, 15, 633.	1.5	3
393	Vaccination reduces viral load and accelerates viral clearance in SARS-CoV-2 Delta variant-infected patients. <i>Annals of Medicine</i> , 2023, 55, 419-427.	1.5	4

#	ARTICLE	IF	CITATIONS
394	Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses. <i>Cell Reports</i> , 2023, 42, 112271.	2.9	12
395	Structural dynamics in the evolution of SARS-CoV-2 spike glycoprotein. <i>Nature Communications</i> , 2023, 14, .	5.8	21
396	Nonsystematic Reporting Biases of the SARS-CoV-2 Variant Mu Could Impact Our Understanding of the Epidemiological Dynamics of Emerging Variants. <i>Genome Biology and Evolution</i> , 2023, 15, .	1.1	1
397	SARS-CoV-2: Structure, Pathogenesis, and Diagnosis. , 2024, , 24-51.		0
398	Potent Omicron-neutralizing antibodies isolated from a patient vaccinated 6 months before Omicron emergence. <i>Cell Reports</i> , 2023, 42, 112421.	2.9	3
399	The importance of combining serological testing with RT-PCR assays for efficient detection of COVID-19 and higher diagnostic accuracy. <i>PeerJ</i> , 0, 11, e15024.	0.9	4
405	The COVID-19 Pandemic: SARS-CoV-2 Structure, Infection, Transmission, Symptomology, and Variants of Concern. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 3-26.	0.8	0
416	Chronicling the 3-year evolution of the COVID-19 pandemic: analysis of disease management, characteristics of major variants, and impacts on pathogenicity. <i>Clinical and Experimental Medicine</i> , 0, , .	1.9	0
418	Interaction of SARS-CoV-2 with host cells and antibodies: experiment and simulation. <i>Chemical Society Reviews</i> , 2023, 52, 6497-6553.	18.7	1
421	Role of cellular fatty acids in combating the corona virus. , 2023, , 439-453.		0
422	Metabolites profiling of ethyl acetate extract of sponge <i>Halichondriidae</i> sp from Kangean Islands and their in silico activity as coronavirus drugs. <i>AIP Conference Proceedings</i> , 2023, , .	0.3	0
436	Importance of Timely Sequencing, Tracking, and Surveillance of Emergent Variants. , 2024, , 166-193.		0